ImmunoGen, Inc. Again Named One of The Boston Globe’s Top Places to Work
14 November 2014 - 8:00AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a
biotechnology company that develops novel anticancer therapeutics
using its antibody-drug conjugate (ADC) technology, today announced
that it has been named one of The Boston Globe’s Top Places to
Work. The Company has received this recognition for the second
consecutive year and in three of the last four years.
Daniel Junius, President and CEO, commented, “We are extremely
pleased that ImmunoGen has once again been recognized as one of The
Boston Globe’s Top Places to Work. We believe that attracting and
retaining the right employees is essential to achieving our mission
of making a difference to patients with cancer.”
The Boston Globe’s 2014 Top Places to Work survey, conducted by
WorkplaceDynamics, measured responses of employees from numerous
organizations in Massachusetts to statements regarding six key
factors related to employee happiness, including company direction,
execution, employee connection, work load and responsibility,
management, and pay and benefits. More than 73,500 individuals
responded to the survey. Among survey respondents, greatest
importance was placed on aspects related to employee appreciation,
confidence and feeling a meaningful connection to the work.
WorkplaceDynamics also found that, of all the cities surveyed,
employees in the Boston area were most enthusiastic about their
companies, making Boston the top of the Top Places to Work.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The
Company’s ADC technology uses tumor-targeting antibodies to deliver
an ImmunoGen cell-killing agent specifically to cancer cells; the
Company has also developed antibodies with anticancer activity of
their own. The first product with ImmunoGen’s ADC technology is
Roche’s Kadcyla®. ImmunoGen has three wholly owned product
candidates in clinical testing with additional compounds in
clinical testing through the Company’s partnerships with Amgen,
Bayer HealthCare, Biotest and Sanofi. More information about
ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Pure Communications,
Inc.Dan Budwick, 973-271-6085
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024